Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia

Zabkiewicz, Joanna ORCID: https://orcid.org/0000-0003-0951-3825, Lazenby, Michelle, Edwards, Gareth, Bygrave, Ceri A., Omidvar, Nader, Zhuang, Lihui, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Guy, Carol, Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan K. and Alvares, Caroline L. ORCID: https://orcid.org/0000-0003-4391-9802 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2) , pp. 231-242. 10.1111/bjh.16665

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Minimal residual disease (MRD) in acute myeloid leukaemia (AML) poses a major challenge due to drug insensitivity and high risk of relapse. Intensification of chemotherapy and stem cell transplantation are often pivoted on MRD status. Relapse rates are high even with the integration of first‐generation FMS‐like tyrosine kinase 3 (FLT3) inhibitors in pre‐ and post‐transplant regimes and as maintenance in FLT3 ‐mutated AML. Pre‐clinical progress is hampered by the lack of suitable modelling of residual disease and post‐therapy relapse. In the present study, we investigated the nature of pro‐survival signalling in primary residual tyrosine kinase inhibitor (TKI)‐treated AML cells adherent to stroma and further determined their drug sensitivity in order to inform rational future therapy combinations. Using a primary human leukaemia‐human stroma model to mimic the cell–cell interactions occurring in patients, the ability of several TKIs in clinical use, to abrogate stroma‐driven leukaemic signalling was determined, and a synergistic combination with a mitogen‐activated protein kinase (MEK) inhibitor identified for potential therapeutic application in the MRD setting. The findings reveal a common mechanism of stroma‐mediated resistance that may be independent of mutational status but can be targeted through rational drug design, to eradicate MRD and reduce treatment‐related toxicity.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Publisher:	Wiley
ISSN:	0007-1048
Date of First Compliant Deposit:	15 April 2020
Date of Acceptance:	23 March 2020
Last Modified:	25 May 2024 10:21
URI:	https://orca.cardiff.ac.uk/id/eprint/131011

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item